IL15RA and neoplasm: Furthermore, to assess whether CD215+ myeloid cells contribute to tumor progression in vivo, we purified CD45+ CD11b+ Gr-1+ CD215+ and CD45+ CD11b+ Gr-1+ CD215− cells from tumor-bearing mice, mixed them with A549 tumor cells, and injected the mixtures into NSI mice.